GlassScriptPhysician profile
Michelle Maxwell Lyon
NPI 1164476479
$1,055.04
in general payments reported to CMS, 2019-2025
18 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.59 · 2021: $108 · 2022: $268 · 2023: $321 · 2024: $138 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mindray Ds USA, INC. | $313.25 | 2022-2024 | Patient Monitor, Na Electrode,Indirect,International |
| Abbvie INC. | $190.62 | 2022-2025 | |
| Livanova USA, INC. | $108.36 | 2021 | |
| Lundbeck LLC | $96.54 | 2022-2025 | Vyepti |
| Pfizer INC. | $56.58 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.69 | 2022 | |
| Tg Therapeutics, INC. | $34.95 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.08 | 2023 | Rexulti |
| Amneal Pharmaceuticals LLC | $24.83 | 2025 | Crexont |
| Promius Pharma LLC | $20.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.09 | 2024 | Hyqvia |
| Janssen Pharmaceuticals, INC | $19.26 | 2022 | |
| Neurocrine Biosciences, INC. | $19.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.48 | 2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $17.84 | 2023 | Soliris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.69 | 2022 | |
| Boston Scientific Corporation | $16.49 | 2024 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $15.57 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.